Biogen Inc stock is traded at $253.40, with a volume of 1,028,895. It is up +1.17% in the last 24 hours and up +10.70% over the past month. Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Previous Close:
$250.48
Open:
$250.58
24h Volume:
1,028,895
Relative Volume:
0.97
Market Cap:
$37.46B
Revenue:
$9.60B
Net Income/Loss:
$1.37B
P/E Ratio:
27.19
EPS:
$9.32
Net Cash Flow:
$2.32B
1W Performance:
+2.03%
1M Performance:
+10.70%
6M Performance:
+23.89%
1Y Performance:
+53.83%
1-Day Range:
$249.52$255.04
1-Week Range:
$246.44$261.00
52-Week Range:
$160.36$261.00
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen IncSector
HealthcareIndustry
Drug Manufacturers - GeneralPhone
(781) 464-2000Address
225 BINNEY STREET, CAMBRIDGE, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS